CJC-1295Studienlage & Dosis

Top-Studien zu CJC-1295

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

1. 01

   Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency.

   J Clin Endocrinol Metab·2002·n=94RCT89 einflussreiche Zitationen

   Although the use of the insulin tolerance test (ITT) for the diagnosis of adult GH deficiency is well established, diagnostic peak GH cut-points for other commonly used GH stimulation tests are less clearly established. Despite that fact,…

2. 02

   Growth hormone-releasing hormone and its analogues in health and disease.

   Nature reviews. Endocrinology·2025D86 einflussreiche Zitationen

   Growth hormone-releasing hormone (GHRH) and its ability to stimulate the production and release of growth hormone from the pituitary were discovered more than four decades ago. Since then, this hormone has been studied extensively and…

3. 03

   A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans.

   J Clin Endocrinol Metab·2001Clinical Trial64 einflussreiche Zitationen

   The synergistic relationship between GH-releasing secretagogue (GHS) and GH-releasing hormone (GHRH) with respect to GH secretion is well known. In the present study, we report a similar relationship between GHRH and ghrelin, a recently…

4. 04

   Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond.

   Reviews in endocrine & metabolic disorders·2025D55 einflussreiche Zitationen

   The regulation of growth hormone (GH) synthesis and secretion by somatotroph cells of the anterior pituitary is a highly complex process, mediated by a variety of neuroendocrine and peripheral influences. In particular, a key role is…

5. 05

   Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.

   J Clin Endocrinol Metab·1998·n=20RCT51 einflussreiche Zitationen

   The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating…

6. 06

   Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.

   J Clin Endocrinol Metab·1996·n=16RCT43 einflussreiche Zitationen

   To compare the effects of oral vs. transdermal estrogens on GH secretion and levels of circulating insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) in younger vs. older postmenopausal women, we conducted a…

7. 07

   Growth hormone - releasing hormone in the immune system.

   Reviews in endocrine & metabolic disorders·2025D43 einflussreiche Zitationen

   GHRH is a neuropeptide associated with a diverse variety of activities in human physiology and immune responses. The present study reviews the latest information on the involvement of GHRH in the immune system and inflammation, suggesting…

8. 08

   A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.

   Cancer Immunol Immunother·2015·n=10Clinical Trial41 einflussreiche Zitationen

   Antigen-specific immunotherapy was studied in a multi-institutional phase 1/2 study by combining decitabine (DAC) followed by an autologous dendritic cell (DC)/MAGE-A1, MAGE-A3 and NY-ESO-1 peptide vaccine in children with…

9. 09

   The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.

   J Clin Endocrinol Metab·1997·n=26RCT38 einflussreiche Zitationen

   Prolonged critical illness is characterized by protein hypercatabolism and preservation of fat depots, associated with blunted GH secretion, elevated serum cortisol levels, and low insulin-like growth factor I (IGF-I) concentrations. In…

10. 10

    Growth hormone for in vitro fertilization.

    Cochrane Database Syst Rev·2010·n=440Meta-Analysis37 einflussreiche Zitationen

    <h4>Background</h4>In an effort to improve outcomes of in-vitro fertilisation cycles the use of growth hormone has been considered. Improving the outcomes of in-vitro fertilisation is especially important for subfertile women who are…

    Befund: Routine adjuvant growth hormone use in in-vitro fertilisation protocols did not improve outcome measures or adverse events overall.

Häufige Fragen

Verwandte Artikel